Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julien Adam

Showing results (61-70 of 152) with videos related to

Pageof 16
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2013
Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancerEmma Pailler, Julien Adam, Amélie Barthélémy, et al.
Cancer Research|May 25, 2017
Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic VirotherapyLaetitia Fend, Takahiro Yamazaki, Christelle Remy, et al.
Molecular Cancer Therapeutics|May 27, 2020
An Antibody-Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor ActivitiesCéline Nicolazzi, Anne Caron, Alexia Tellier, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 29, 2017
Prognostic value of tissue necrosis, hypoxia-related markers and correlation with HPV status in head and neck cancer patients treated with bio- or chemo-radiotherapyDan Ou, Ingrid Garberis, Julien Adam, et al.
Oncoimmunology|September 22, 2017
Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapyDan Ou, Julien Adam, Ingrid Garberis, et al.
Cardiovascular and Interventional Radiology|November 7, 2019
Correction to: Focus on Recommendations for the Management of Non-small Cell Lung CancerPernelle Lavaud, Benjamin Besse, Thierry de Baere, et al.
Frontiers in Immunology|March 21, 2020
IDO Targeting in Sarcoma: Biological and Clinical ImplicationsImane Nafia, Maud Toulmonde, Doriane Bortolotto, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 23, 2019
Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitorsRomain-David Seban, Laura Mezquita, Arnaud Berenbaum, et al.
Cancer Biomarkers : Section a of Disease Markers|November 2, 2016
MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancerJulien Adam, Tony Sourisseau, Ken A Olaussen, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 2017
Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoidsIvana Sullivan, Gwénaël Le Teuff, Joël Guigay, et al.
Pageof 16

Showing results (61-70 of 152) with videos related to

Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2013
Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancerEmma Pailler, Julien Adam, Amélie Barthélémy, et al.
Cancer Research|May 25, 2017
Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic VirotherapyLaetitia Fend, Takahiro Yamazaki, Christelle Remy, et al.
Molecular Cancer Therapeutics|May 27, 2020
An Antibody-Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor ActivitiesCéline Nicolazzi, Anne Caron, Alexia Tellier, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 29, 2017
Prognostic value of tissue necrosis, hypoxia-related markers and correlation with HPV status in head and neck cancer patients treated with bio- or chemo-radiotherapyDan Ou, Ingrid Garberis, Julien Adam, et al.
Oncoimmunology|September 22, 2017
Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapyDan Ou, Julien Adam, Ingrid Garberis, et al.
Cardiovascular and Interventional Radiology|November 7, 2019
Correction to: Focus on Recommendations for the Management of Non-small Cell Lung CancerPernelle Lavaud, Benjamin Besse, Thierry de Baere, et al.
Frontiers in Immunology|March 21, 2020
IDO Targeting in Sarcoma: Biological and Clinical ImplicationsImane Nafia, Maud Toulmonde, Doriane Bortolotto, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 23, 2019
Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitorsRomain-David Seban, Laura Mezquita, Arnaud Berenbaum, et al.
Cancer Biomarkers : Section a of Disease Markers|November 2, 2016
MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancerJulien Adam, Tony Sourisseau, Ken A Olaussen, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 2017
Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoidsIvana Sullivan, Gwénaël Le Teuff, Joël Guigay, et al.
Pageof 16